Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus-Reference-Cited by-同舟云学术

Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus

Published:2008-03 Issue:3 Volume:52 Page:1153-1155
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sader Helio S.¹²,Fritsche Thomas R.¹,Jones Ronald N.¹³

Affiliation:

1. JMI Laboratories, North Liberty, Iowa

2. Universidade Federal de Sao Paulo, Sao Paulo, Brazil

3. Tufts University School of Medicine, Boston, Massachusetts

Abstract

ABSTRACT Two investigational anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) β-lactams, ceftaroline (a cephalosporin) and ME1036 (a carbapenem), were subjected to susceptibility testing by reference broth microdilution methods using 152 strains of community-acquired MRSA from the United States (47 medical centers). Ceftaroline and ME1036 were 64- and >128-fold more potent than ceftriaxone, respectively. All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01351-07

Reference17 articles.

1. Bush, K., M. Heep, M. J. Macielag, and G. J. Noel. 2007. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs16:419-429.

2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2006

3. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. 2007

4. Deurenberg, R. H., C. Vink, S. Kalenic, A. W. Friedrich, C. A. Bruggeman, and E. E. Stobberingh. 2007. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect.13:222-235.

5. Iizawa, Y., J. Nagai, T. Ishikawa, S. Hashiguchi, M. Nakao, A. Miyake, and K. Okonogi. 2004. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother.10:146-156.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital;Indian Journal of Medical Microbiology;2021-09

2. Quantification of Ceftaroline in Human Plasma Using High-Performance Liquid Chromatography with Ultraviolet Detection: Application to Pharmacokinetic Studies;Pharmaceutics;2021-06-25

3. Penicillin binding protein 2a: An overview and a medicinal chemistry perspective;European Journal of Medicinal Chemistry;2020-08

4. Community-acquired pneumonia in hospitalized patients: clinical guidelines;Medical Council;2019-12-08

5. CEFTAROLINE: A NEW CEPHALOSPORIN WITH ACTIVITY AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA);INDO AM J PHARM SCI;2019